Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Sunosi active ingredient?

See the DrugPatentWatch profile for Sunosi

The active ingredient in Sunosi is solriamfetol [1].

What is Solriamfetol used for?


Solriamfetol is used to treat excessive daytime sleepiness (EDS) in adults with narcolepsy or obstructive sleep apnea (OSA) [1]. It works by increasing the levels of dopamine and norepinephrine in the brain, which helps to promote wakefulness [2].

How does Solriamfetol work?


Solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) [1]. It binds to and inhibits the reuptake transporters for dopamine (DAT) and norepinephrine (NET) [2]. By blocking these transporters, solriamfetol increases the extracellular concentrations of dopamine and norepinephrine in the brain, leading to increased wakefulness [2].

When was Solriamfetol approved?


Solriamfetol was approved by the U.S. Food and Drug Administration (FDA) in March 2019 [1].

Are there any alternatives to Solriamfetol?


For the treatment of EDS in narcolepsy, other approved medications include modafinil, armodafinil, and sodium oxybate [3]. For EDS in OSA, modafinil and armodafinil are also commonly prescribed [3].

What are the potential side effects of Solriamfetol?


Common side effects of solriamfetol include headache, nausea, decreased appetite, insomnia, anxiety, and increased blood pressure [1]. Patients are advised to inform their healthcare provider about any side effects experienced [1].

What is the patent status for Solriamfetol?


Information on specific patents and their expiration dates for solriamfetol can be found on DrugPatentWatch.com [4]. DrugPatentWatch.com tracks patent landscapes, exclusivity periods, and potential generic entry timelines for pharmaceutical products.

Sources:
1. https://www.novartis.com/news/media-releases/fda-approves-sunosi-solriamfetol-tablets-treatment-excessive-daytime-sleepiness-adults-narcolepsy-obstructive-sleep-apnea
2. https://pubmed.ncbi.nlm.nih.gov/30005054/
3. https://www.uptodate.com/contents/pharmacotherapy-for-excessive-daytime-sleepiness-in-narcolepsy-and-other-hypersomnias-of-central-origin
4. https://drugpatentwatch.com/



Other Questions About Sunosi :

Sunosi generic? Sunosi generic? Sunosi generic? Sunosi vs modafinil?